Prognostic factors in neuroendocrine small cell cervical carcinoma
- 17 January 2003
- Vol. 97 (3), 568-574
- https://doi.org/10.1002/cncr.11086
Abstract
The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma. All patients with NE cervical carcinoma diagnosed between 1979–2001 were identified from tumor registry databases at two hospitals. Data were collected from hospital charts, office records, and tumor registry files. The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan–Meier life table analyses and log-rank tests. The independent prognostic factors found to be predictive of survival in univariate analysis were evaluated using Cox regression. All tests were two-tailed with P values < 0.05 considered significant. Thirty-four patients (median age, 42 years) were diagnosed with neuroendocrine cervical carcinoma, which included 21 with International Federation of Gynecology and Obstetrics (FIGO) Stage I disease, 6 with FIGO Stage II disease, 5 with FIGO Stage III disease, and 2 with FIGO Stage IV disease. Seventeen patients underwent a radical and 6 patients underwent a simple hysterectomy. Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy. Ten women received primary radiotherapy with (n = 5) or without (n = 4) chemotherapy and the remaining patient refused therapy. Women with early-stage (Stage I-IIA) disease had median survival rates of 31 months compared with 10 months in the advanced-stage (Stage IIB-IVB) group (P = 0.002). In univariate analysis, advanced stage (P = 0.002), tumor size >2 cm (P = 0.02), margin involvement (P = 0.016), pure versus a mixed histologic pattern (P = 0.04), margin status (P = 0.016), and smoking (P = 0.04) were considered poor prognostic factors. In multivariate analysis, smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival. Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix. Only those with early lesions amenable to extirpation are cured. The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions. Clinical trials are needed. Cancer 2003;97:568–74. © 2003 American Cancer Society. DOI 10.1002/cncr.11086Keywords
This publication has 18 references indexed in Scilit:
- Neuroendocrine Cervical Carcinoma: A Diagnostic and Therapeutic ChallengeGynecologic Oncology, 2001
- Multimodality Therapy in Early-Stage Neuroendocrine Carcinoma of the Uterine CervixGynecologic Oncology, 2001
- The effect of stopping smoking on cervical Langerhans'cells and lymphocytesBJOG: An International Journal of Obstetrics and Gynaecology, 2001
- A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinomaCancer, 1998
- Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposideGynecologic Oncology, 1992
- Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- Small-Cell Neuroendocrine Carcinoma of the CervixThe American Journal of Surgical Pathology, 1991
- An immunohistochemical study of small-cell and poorly differentiated carcinomas of the cervix using neuroendocrine markersGynecologic Oncology, 1989
- Small-Cell Undifferentiated Carcinoma of the CervixThe American Journal of Surgical Pathology, 1988
- Neuroendocrine carcinoma of the cervix: Implications for staging and therapyGynecologic Oncology, 1981